TIL cell therapy for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This early-stage trial tests a type of immune cell treatment (TILs) made from your tumor to treat advanced solid cancers. It may help if standard treatments have failed or aren’t an option, but you must be able to provide enough tumor tissue for cell collection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You expect to live at least 3 months
- You can take care of yourself most of the day (ECOG 0–1)
- You have an advanced solid tumor confirmed by biopsy, such as melanoma or certain head/neck, lung, cervical, ovarian, or esophageal cancers, and standard treatment is no longer working or isn’t possible
- Your doctor can remove or biopsy enough tumor tissue: one or more target areas (at least 6 biopsy-accessible lesions) or one larger area (>1.5 cm³)
- You have at least one measurable tumor spot that can be tracked on scans (RECIST v1.1)
- Your blood and organ tests are strong enough for treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests a treatment made from your own tumor-fighting immune cells (TIL cells) for advanced solid cancers that have worsened or no longer respond to standard therapy. The main goal is to learn whether it is safe and whether it can shrink tumors for people who have limited options.
This trial tests an immunotherapy made from your own tumor-fighting immune cells (TIL). It may help people with advanced solid cancers that cannot be cured with surgery or radiation.
This trial tests an investigational treatment called LM303 for people with advanced solid tumors like melanoma, lung cancer, or cervical cancer. It uses your own immune cells (called TILs) to fight the cancer, so you need a tumor large enough for cells to be collected.
This early-phase study tests LM103 in people with advanced solid cancers that have not responded to standard treatments or where standard options are not suitable. It mainly focuses on whether LM103 can be safely given and whether it can shrink tumors or help control the disease.
This trial tests a type of immune cell treatment called TIL (tumor-infiltrating lymphocytes) in people with advanced solid cancers. It may help your immune system better recognize and attack tumors, especially if standard treatments have not worked.
This Phase 1 study tests LM103 to treat advanced cancers that are not responding to standard treatment. It also looks at whether enough tumor tissue can be collected for immune cell testing, and focuses on safety at first.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.